Differential Effects of IL-12 on Tregs and Non-Treg T Cells: Roles of IFN-γ, IL-2 and IL-2R

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Zhao, Jingxian ^a,b   Zhao, Jincun ^a   Perlman, Stanley ^a  

^a UNIVERSITY OF IOWA   (United States)

^b JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 27; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL GROWTH; CONTROLLED STUDY; CYTOKINE PRODUCTION; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD4; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKINS; MICE; ORGAN SPECIFICITY; RECEPTORS, INTERLEUKIN-2; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 84866893829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046241     Document Type: Article

References (50)

1. Vignali DA, Collison LW, Workman CJ, (2008) How regulatory T cells work. Nat Rev Immunol 8: 523-532.
2. Belkaid Y, (2007) Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 7: 875-888.
3. Wing K, Sakaguchi S, (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11: 7-13.
4. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
5. Oldenhove G, Bouladoux N, Wohlfert EA, Hall JA, Chou D, et al. (2009) Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 31: 772-786.
6. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, et al. (2009) Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458: 351-356.
7. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, et al. (2009) The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 10: 595-602.
8. Zhao J, Zhao J, Fett C, Trandem K, Fleming E, et al. (2011) IFN-gamma- and IL-10-expressing virus epitope-specific Foxp3(+) T reg cells in the central nervous system during encephalomyelitis. J Exp Med 208: 1571-1577.
9. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, et al. (2007) Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 13: 423-431.
10. Pasare C, Medzhitov R, (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
11. Wan S, Xia C, Morel L, (2007) IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J Immunol 178: 271-279.
12. King IL, Segal BM, (2005) Cutting edge: IL-12 induces CD4+CD25- T cell activation in the presence of T regulatory cells. J Immunol 175: 641-645.
13. Feng T, Cao AT, Weaver CT, Elson CO, Cong Y, (2011) Interleukin-12 converts Foxp3+ regulatory T cells to interferon-gamma-producing Foxp3+ T cells that inhibit colitis. Gastroenterology 140: 2031-2043.
14. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, et al. (2000) Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 60: 3239-3246.
15. Bergmann CC, Lane TE, Stohlman SA, (2006) Coronavirus infection of the central nervous system: host-virus stand-off. Nat Rev Microbiol 4: 121-132.
16. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B, (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189.
17. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
18. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, et al. (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231-234.
19. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, et al. (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669.
20. Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, et al. (2001) Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 292: 1907-1910.
21. Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F, (2008) Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev 226: 112-131.
22. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, et al. (2009) Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 10: 1000-1007.
23. Miyao T, Floess S, Setoguchi R, Luche H, Fehling HJ, et al. (2012) Plasticity of Foxp3(+) T Cells Reflects Promiscuous Foxp3 Expression in Conventional T Cells but Not Reprogramming of Regulatory T Cells. Immunity 36: 262-275.
24. Rubtsov YP, Niec RE, Josefowicz S, Li L, Darce J, et al. (2010) Stability of the regulatory T cell lineage in vivo. Science 329: 1667-1671.
25. Bayer AL, Yu A, Malek TR, (2007) Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells. J Immunol 178: 4062-4071.
26. Bayer AL, Yu A, Adeegbe D, Malek TR, (2005) Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J Exp Med 201: 769-777.
27. Setoguchi R, Hori S, Takahashi T, Sakaguchi S, (2005) Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723-735.
28. Malek TR, Castro I, (2010) Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33: 153-165.
29. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, et al. (2007) Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 39: 329-337.
30. Villarino AV, Stumhofer JS, Saris CJ, Kastelein RA, de Sauvage FJ, et al. (2006) IL-27 limits IL-2 production during Th1 differentiation. J Immunol 176: 237-247.
31. D'Souza WN, Lefrancois L, (2003) IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J Immunol 171: 5727-5735.
32. Yu A, Zhou J, Marten N, Bergmann CC, Mammolenti M, et al. (2003) Efficient induction of primary and secondary T cell-dependent immune responses in vivo in the absence of functional IL-2 and IL-15 receptors. J Immunol 170: 236-242.
33. D'Souza WN, Schluns KS, Masopust D, Lefrancois L, (2002) Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses. J Immunol 168: 5566-5572.
34. Valenzuela J, Schmidt C, Mescher M, (2002) The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol 169: 6842-6849.
35. Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, et al. (2010) Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 59: 407-415.
36. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, et al. (2008) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28: 687-697.
37. Lazarski CA, Hughson A, Sojka DK, Fowell DJ (2008) Regulating Treg cells at sites of inflammation. Immunity 29: 511; author reply 512.
38. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, et al. (2011) Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365: 2067-2077.
39. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, et al. (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365: 2055-2066.
40. Ahmadzadeh M, Rosenberg SA, (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107: 2409-2414.
41. Lemoine FM, Cherai M, Giverne C, Dimitri D, Rosenzwajg M, et al. (2009) Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol 35: 569-581.
42. Villarino A, Hibbert L, Lieberman L, Wilson E, Mak T, et al. (2003) The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19: 645-655.
43. Yoshimura T, Takeda A, Hamano S, Miyazaki Y, Kinjyo I, et al. (2006) Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J Immunol 177: 5377-5385.
44. Yoshida H, Nakaya M, Miyazaki Y, (2009) Interleukin 27: a double-edged sword for offense and defense. J Leukoc Biol 86: 1295-1303.
45. Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, et al. (2001) WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 15: 569-578.
46. Wojno ED, Hosken N, Stumhofer JS, O'Hara AC, Mauldin E, et al. (2011) A role for IL-27 in limiting T regulatory cell populations. J Immunol 187: 266-273.
47. Wan YY, Flavell RA, (2007) Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445: 766-770.
48. Fleming JO, Trousdale MD, el-Zaatari FA, Stohlman SA, Weiner LP, (1986) Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies. J Virol 58: 869-875.
49. Kapil P, Atkinson R, Ramakrishna C, Cua DJ, Bergmann CC, et al. (2009) Interleukin-12 (IL-12), but not IL-23, deficiency ameliorates viral encephalitis without affecting viral control. J Virol 83: 5978-5986.
50. Xing Z, (2001) Breach of IL-12 monopoly in the initiation of type 1 immunity to intracellular infections: IL-12 is not required. Cell Mol Biol (Noisy-le-grand) 47: 689-694.